These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2403095)

  • 1. Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia.
    Koren G; Langevin AM; Olivieri N; Giesbrecht E; Zipursky A; Greenberg M
    Am J Dis Child; 1990 Oct; 144(10):1135-7. PubMed ID: 2403095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
    Schmiegelow K; Ifversen M
    Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy?
    Balis FM; Jeffries SL; Lange B; Murphy RF; Doherty KM; Arndt CA; Luery N; Poplack DG
    Am J Pediatr Hematol Oncol; 1989; 11(3):324-6. PubMed ID: 2782561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.
    Koren G; Ferrazini G; Sulh H; Langevin AM; Kapelushnik J; Klein J; Giesbrecht E; Soldin S; Greenberg M
    N Engl J Med; 1990 Jul; 323(1):17-21. PubMed ID: 2355954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
    Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K;
    Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO).
    Schmiegelow K; Glomstein A; Kristinsson J; Salmi T; Schrøder H; Björk O
    J Pediatr Hematol Oncol; 1997; 19(2):102-9. PubMed ID: 9149738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Schmiegelow K; Bretton-Meyer U
    Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
    Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
    Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics.
    Koren G; Solh H; Klein J; Soldin SJ; Greenberg M
    Med Pediatr Oncol; 1989; 17(6):450-4. PubMed ID: 2586358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pattern of 6-mercaptopurine urinary excretion in children with acute lymphoblastic leukemia: urinary assays as a measure of drug compliance.
    Macdougall LG; McElligott SE; Ross E; Greeff MC; Poole JE
    Ther Drug Monit; 1992 Oct; 14(5):371-5. PubMed ID: 1448843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circadian time-dependent response of childhood lymphoblastic leukemia to chemotherapy: a long-term follow-up study of survival.
    Rivard GE; Infante-Rivard C; Dresse MF; Leclerc JM; Champagne J
    Chronobiol Int; 1993 Jun; 10(3):201-4. PubMed ID: 8319318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?
    Schmiegelow K; Nersting J; Nielsen SN; Heyman M; Wesenberg F; Kristinsson J; Vettenranta K; Schrøeder H; Weinshilboum R; Jensen KL; Grell K; Rosthoej S
    Pediatr Blood Cancer; 2016 Dec; 63(12):2104-2111. PubMed ID: 27447547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
    Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia.
    Kato Y; Matsushita T; Chiba K; Hijiya N; Yokoyama T; Ishizaki T
    J Pediatr; 1991 Aug; 119(2):311-6. PubMed ID: 1861221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. White cell count during maintenance chemotherapy for standard-risk childhood acute lymphoblastic leukemia: relation to relapse rate.
    Schmiegelow K; Pulczynska MK; Seip M
    Pediatr Hematol Oncol; 1988; 5(4):259-67. PubMed ID: 3152971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance chemotherapy for childhood acute lymphoblastic leukaemia: better in the evening.
    Rivard GE; Infante-Rivard C; Hoyoux C; Champagne J
    Lancet; 1985 Dec; 2(8467):1264-6. PubMed ID: 2866334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
    Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
    Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
    Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
    J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity.
    Hayder S; Lafolie P; Björk O; Peterson C
    Ther Drug Monit; 1989 Nov; 11(6):617-22. PubMed ID: 2595740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
    Larsen RH; Hjalgrim LL; Grell K; Kristensen K; Pedersen LG; Brünner ED; Als-Nielsen B; Schmiegelow K; Nersting J
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):25-32. PubMed ID: 32519032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.